COMMUNIQUÉS West-GlobeNewswire

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants
30/07/2025
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of [...]
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
30/07/2025
On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy. Q2 2025 shows 10 th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local [...]
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
30/07/2025
LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will [...]
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
30/07/2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and [...]
Novasight™ Hybrid Imaging System Featured in Published JSCAI Case Report Demonstrating Superior Diagnosis and Precision-Guided Therapy in Complex Coronary Case
30/07/2025
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intravascular imaging, is pleased to announce the publication of a compelling case report in the Journal of [...]
Amarin Reports Second Quarter 2025 Financial Results
30/07/2025
-- European Partnership with Recordati Established to Maximize VAZKEPA ® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 [...]
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
30/07/2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health [...]
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
30/07/2025
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2025
30/07/2025
BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
30/07/2025
Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end [...]
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
30/07/2025
Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company [...]
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
30/07/2025
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed [...]
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
30/07/2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar [...]
AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA
30/07/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE A RECU L’APPROBATION REGLEMENTAIRE DE PAYS EUROPEENS POUR INITIER LA TROISIEME ETAPE DE LA PHASE I/II VISANT A COMBINER SA MOLÉCULE AB8939 AVEC LE VENETOCLAX DANS LE TRAITEMENT DE LA [...]
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
30/07/2025
PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE [...]
Leading European Shipbuilder Selects Aino’s SaaS Platform
30/07/2025
Aino Health AB (publ) has signed an agreement with one of Europe’s leading shipbuilding companies for the implementation of the Aino SaaS platform. The agreement covers 2,000 employees and aims to strengthen the [...]
Clenbuterol for Sale: The Complete Guide to Buying Real Clen Pills Online Without Getting Scammed
30/07/2025
Clenbuterol for Sale: Where to Buy Real Clen Pills Online Without Risking Your Health or Wallet In recent years, Clenbuterol has surged in popularity among athletes and bodybuilders looking for an effective way to shed [...]
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
30/07/2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
30/07/2025
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the same period in 2024, [...]

Pages